Commission Implementing Regulation (EU) 2020/1685 of 12 November 2020 amending Regulation (EU) No 37/2010 to classify the substance bupivacaine as regards its maximum residue limit (Text with EEA relevance)

• CELEX: Implementing Regulation (EU) 2020/1685
• Articles: 3

Article 1

The Annex to Regulation (EU) No 37/2010 is amended as set out in the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

In Table 1 of the Annex to Regulation (EU) No 37/2010, an entry for the following substance is inserted in alphabetical order:

Pharmacologically active Substance

Marker residue

Animal Species

MRLs

Target Tissues

Other Provisions (according to Article 14(7) of Regulation (EC) No 470/2009)

Therapeutic Classification

‘Bupivacaine

NOT APPLICABLE

Porcine

No MRL required

NOT APPLICABLE

For use in piglets up to 7 days of age only.

For cutaneous and epilesional use only.

Local anaesthetic’

Bovine

For use in calves up to 2 months of age only.

For cutaneous and epilesional use only.